RBC raised target for Gilead Sciences stock to USD 126.00
Published on 10/12/2026 at 12:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- RBC Capital Markets raised its Gilead Sciences price target from USD 123.00 to USD 126.00 on October 8, 2026.
- Second-quarter revenue rose 10.2 percent year over year to USD 7.80 billion and exceeded expectations by 6.2 percent.
- Gilead Sciences stock was at EUR 135.63 at Lang & Schwarz on October 12, 2026, up 1.49 percent versus the Xetra close of EUR 133.64.
- The next earnings report is listed for October 29, 2026, after the close.
Gilead Sciences (ISIN US3755581036) was at EUR 135.63 at Lang & Schwarz on October 12, 2026 at 12:20 p.m. CEST, up 1.49 percent versus the Xetra close of EUR 133.64. On October 8, 2026, RBC Capital Markets raised its price target from USD 123.00 to USD 126.00 while retaining its Sector Perform rating, as Markets Insider reported.
Three October events reshaped the story
On October 6, 2026, Cognizant announced a five-year extension of its work with Gilead Sciences, according to MarketWatch. On October 7, 2026, Truist raised its price target from USD 150.00 to USD 158.00, the same MarketWatch news listing reported. On October 8, 2026, RBC Capital Markets moved its target from USD 123.00 to USD 126.00, a change documented by Markets Insider.
What does the revenue beat mean?
Gilead reported USD 7.80 billion of revenue in the second quarter of 2026, up 10.2 percent year over year and 6.2 percent above analysts' expectations, according to Yahoo Finance. The combination of double-digit revenue growth and the target changes gives the market two distinct reference points, although the revenue result alone does not settle the valuation debate.
Analysts split at USD 126 and USD 155
RBC's USD 126.00 target sits below the USD 155.00 target that Cantor Fitzgerald retained with an Overweight rating on October 8, 2026. Both analyst actions were listed by The Globe and Mail, while the RBC target change was also detailed by Markets Insider. The spread between the two targets shows that the revenue improvement has not produced a uniform analyst view.
Next earnings date is October 29
Gilead's next earnings report is listed for October 29, 2026, after the close, by Gekko. The page lists consensus expectations of USD 2.12 in earnings per share and USD 7.77 billion in revenue for that report, both of which provide concrete markers for the next results reaction.
Nasdaq range remains wide
On Nasdaq, Gilead's October 9, 2026 52-week range was USD 114.02 to USD 157.29, while market capitalization stood at USD 187.4 billion. At Lang & Schwarz, the stock was trading at EUR 135.63 on October 12, 2026 at 12:20 p.m. CEST, or 1.49 percent above the Xetra close of October 9, 2026 at EUR 133.64. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 12, 2026, 12:20 p.m. CEST): EUR 135.63
- Change versus Xetra close: plus 1.49 percent
- Xetra close (October 9, 2026): EUR 133.64
- Market capitalization: USD 187.4 billion (as of October 9, 2026)
- 52-week range: USD 114.02-157.29 (as of October 9, 2026)
- Sector / Industry: Health Care / Biotechnology
- Next earnings date: October 29, 2026
Market context: Market report Nasdaq Composite.
